---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-043554"
form_type: "8-K"
ticker: "RNLXY"
cik: "0001811115"
company_name: "Renalytix plc"
filed_at: "2023-08-21T23:59:59+00:00"
generated_at: "2026-06-11T06:24:31.582027+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Renalytix's KidneyIntelX included in draft KDIGO 2023 chronic kidney disease guidelines

## Summary
- Public comment period on draft KDIGO 2023 guidelines closed; final version expected Q4 2023.
- KDIGO is a global nonprofit; guidelines are followed by clinicians worldwide.
- Inclusion, if finalized, could drive broader adoption and reimbursement for KidneyIntelX in US and abroad.
- Renalytix notes inclusion in draft does not guarantee inclusion in final guidelines.

## SEC filing metadata
- accession: 0000950170-23-043554
- form_type: 8-K
- ticker: RNLXY
- cik: 0001811115
- company_name: Renalytix plc
- filed_at: 2023-08-21T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811115/000095017023043554/0000950170-23-043554-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811115/000095017023043554/rnlx-20230821.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-043554
- JSON: https://secwatch.observer/filing/0000950170-23-043554.json
- Plain text: https://secwatch.observer/filing/0000950170-23-043554.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.